CryoPort Inc Dossier - Source-backed chat

CryoPort Inc

CYRXNASDAQ

SectorHealth Care

IndustryLife Sciences Tools & Services

Beta (adjusted)1.58

Intrinsic Value $14.50median of 2 methodsbased on filings through 30 Jun 2026

Market Price $17.36Price as of 1 Oct 2026

OvervaluedIntrinsic value is 16% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $879.3M

Enterprise Value $796.2M

Shares Outstanding 50.1M diluted

Next Earnings Date11 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Cryoport, Inc. is a leading global provider of integrated temperature-controlled supply chain solutions tailored for the high-growth cell and gene therapy (CGT) market. Following the strategic divestiture of its CRYOPDP specialty courier business to DHL in mid-2025, Cryoport has transitioned into a pure-play, higher-margin platform. The company is demonstrating strong top-line momentum, with Q1 2026 revenue growing 16% year-over-year to $47.8 million, driven by robust demand in both Life Sciences Services and Products. With a record 766 global clinical trials supported and 21 commercial therapies online, Cryoport is uniquely positioned to capture the commercial ramp of advanced therapeutics. While near-term profitability remains a headwind, the company's strong balance sheet ($403.6 million in cash and short-term investments) and clear path to positive Adjusted EBITDA in H2 2026 support a highly favorable risk-reward profile.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets9 analysts · as of 18 Aug 2026

Low · most bearish analyst$12.00

Mean target$16.17

High · most bullish analyst$20.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$12.0015%

Persistent macroeconomic headwinds, funding constraints for early-stage biotech clients, or delays in clinical trials slow down the pipeline conversion. Elevated transportation costs and underutilization of new facilities delay the path to Adjusted EBITDA profitability into 2027, leading to multiple compression and downward revisions of analyst targets.

Base CaseCentral scenario

$15.3060%

Cryoport achieves its raised FY 2026 revenue guidance of $192 million to $196 million, representing 9% to 11% organic growth. The company successfully achieves positive Adjusted EBITDA in the second half of 2026 through disciplined cost management and steady commercial therapy rollouts. Valuation aligns with the consensus analyst target as clinical trials continue to transition to commercial phases.

Bull CaseUpside scenario

$25.0025%

Accelerated commercial CGT approvals and rapid ramp-up of new facilities (Paris and Santa Ana) drive organic revenue growth above 15% for FY 2026. Operating leverage builds faster than expected, leading to substantial gross margin expansion and positive Adjusted EBITDA starting in Q3 2026. Multiple expansion occurs as the market recognizes Cryoport's high-barrier-to-entry moat in cryogenic logistics.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Pure-play exposure to the rapidly expanding cell and gene therapy (CGT) market with high barriers to entry.
Strong balance sheet with over $400 million in cash and short-term investments, providing significant financial flexibility.
Robust clinical pipeline supporting 766 global trials, ensuring a steady stream of future commercial revenue opportunities.
Strategic partnership with DHL and divestiture of CRYOPDP, optimizing the business model toward higher-margin services.

Key Investment Risks

Near-term profitability pressures with continued net losses and negative operating cash flows.
Sensitivity to biotech funding cycles and potential delays in customer clinical trials.
Execution risks associated with the geographic expansion and ramp-up of new global supply chain centers.
High valuation volatility typical of small-cap life sciences infrastructure providers.

Thesis Invalidation Triggers

Failure to achieve positive Adjusted EBITDA in the second half of 2026.
A significant drop in the number of supported Phase III clinical trials or commercial therapies.
Material market share loss to specialized logistics competitors or in-house solutions by major biopharma companies.
Severe regulatory or operational failures resulting in compromised shipments of critical patient therapies.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.